Though it now has an FDA advisory committee endorsement in its pocket, Bristol-Myers Squibb Co. and AstraZeneca PLC’s Farxiga (dapagliflozin) could face a difficult competitive environment if approved, given lingering concerns about bladder cancer risk and restrictions against use in type 2 diabetics with moderate to severe renal impairment.
The safety-related concerns, coupled with its second-in-class status, could prove a challenge for dapagliflozin as it attempts to cut into...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?